MIDTERM NURS 6635 PSYCHOPATHERAPY REVIEW IN
PROGRESS PSYCHIATRIC MENTAL HEALTH
anxiety, 10 OCD
A benzodiazepine antagonist, flumazenil
(Romazicon), causes - ANS frequent severe panic
attacks in patients with panic disorder. p.390
low-potency benzodiazepines are most effective for
the symptoms - ANS of generalized anxiety disorder
p. 390
high-potency benzodiazepines, such as alprazolam
(Xanax), and clonazepam are effective in the
treatment - ANS of panic disorder p.390
in patients with panic disorder, β-adrenergic
receptor agonists (e.g., isoproterenol [Isuprel]) and
α2-adrenergic receptor antagonists (e.g., yohimbine
[Yocon]) - ANS can provoke frequent and severe
panic attacks. p. 390
, Conversely, clonidine (Catapres), an α2-receptor
agonist, - ANS reduces anxiety symptoms in some
experimental and therapeutic situations. p.390
Galanin and NPY receptor agonists may be novel
targets - ANS for antianxiety drug development. p.
390-391
The gene codes for stathmin, a protein that is -
ANS critical for the amygdala to form fear memories
p. 391
In addition to receiving noradrenergic and
serotonergic innervation, the limbic system also
contains a high concentration of - ANS GABA-A
receptors p. 391
The temporal cortex has also been implicated as -
ANS a pathophysiological site in anxiety disorders.
p. 391
Patients with panic disorder present with a number
of comorbid conditions, - ANS most commonly
agoraphobia, which refers to a fear of or anxiety
regarding places from which escape might be
difficult. p.392
PROGRESS PSYCHIATRIC MENTAL HEALTH
anxiety, 10 OCD
A benzodiazepine antagonist, flumazenil
(Romazicon), causes - ANS frequent severe panic
attacks in patients with panic disorder. p.390
low-potency benzodiazepines are most effective for
the symptoms - ANS of generalized anxiety disorder
p. 390
high-potency benzodiazepines, such as alprazolam
(Xanax), and clonazepam are effective in the
treatment - ANS of panic disorder p.390
in patients with panic disorder, β-adrenergic
receptor agonists (e.g., isoproterenol [Isuprel]) and
α2-adrenergic receptor antagonists (e.g., yohimbine
[Yocon]) - ANS can provoke frequent and severe
panic attacks. p. 390
, Conversely, clonidine (Catapres), an α2-receptor
agonist, - ANS reduces anxiety symptoms in some
experimental and therapeutic situations. p.390
Galanin and NPY receptor agonists may be novel
targets - ANS for antianxiety drug development. p.
390-391
The gene codes for stathmin, a protein that is -
ANS critical for the amygdala to form fear memories
p. 391
In addition to receiving noradrenergic and
serotonergic innervation, the limbic system also
contains a high concentration of - ANS GABA-A
receptors p. 391
The temporal cortex has also been implicated as -
ANS a pathophysiological site in anxiety disorders.
p. 391
Patients with panic disorder present with a number
of comorbid conditions, - ANS most commonly
agoraphobia, which refers to a fear of or anxiety
regarding places from which escape might be
difficult. p.392
